Skip to main content

MANGOCEUTICALS, INC.

corporate_fare Company Profile

MANGOCEUTICALS, INC.

MGRX·NASDAQ·Healthcare·CIK 0001938046

Mangoceuticals, Inc. develops, markets, and sells men's wellness products and services in the United States, primarily through a telemedicine platform. The company offers erectile dysfunction products under the Mango brand, hair loss products under the Grow brand, hormone balance and therapy products under the Mojo brand, and weight loss products under the Slim brand. It also provides oral testosterone undecanoate, marketed under the Prime brand, to treat low testosterone in men and for testosterone replacement therapy. Mangoceuticals facilitates customer access to a licensed pharmacy for online fulfillment and distribution of medications prescribed during telehealth consultations. The company markets and sells its products online via its website, www.MangoRX.com. Incorporated in 2021, Mangoceuticals, Inc. is headquartered in Dallas, Texas, and operates as a subsidiary of Cohen Enterprises, Inc.

MANGOCEUTICALS, INC. (NASDAQ:MGRX) is a publicly traded company in the Healthcare sector. Wiseek monitors MGRX SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Mangoceuticals Reports Severe Cash Drain, Reiterates Going Concern, Faces Nasdaq Delisting, and Discloses Controversial CEO Subsidiary Agreement
  • MANGOCEUTICALS Faces Delisting Amid Soaring Losses, CEO Option Repricing, and Related Party Control of Core Assets
  • Mangoceuticals Reprices CEO Options, Files $73M Lawsuit Against Former Consultant
  • Mangoceuticals Sues Former Tech Firm for $73M+ Over Failed Platform Delivery
  • Mangoceuticals Seeks Patent Expansion for MGX-0024 Antiviral to Cover Animal and Bird Infections

monitoring Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$456.02K
Net Income
-$20.64M
Diluted EPS
-$2.17
Op. Cash Flow
-$5.85M
Gross Profit
$250.39K
Operating Income
-$18.03M
Cash & Equivalents
$1.49M
Debt / Equity
0.00×
Net Margin
-45.27×
Shares Outstanding
15.89M sh
Source: 10-K · filed 2026-04-01 · accession 0001493152-26-014478

supervised_user_circle Insider Transactions

$174.01K sold
Net $174.01K selling · 4 transactions by 2 insiders · last 12 months
  • 2025-12-15 JOHNSTON EUGENE M CFO Officer
    Open-market sale 3.33K sh $3.88K @ $1.17
  • 2025-12-09 JOHNSTON EUGENE M CFO Officer
    Open-market sale 5K sh $5.97K @ $1.20
  • 2025-12-05 JOHNSTON EUGENE M CFO Officer
    Open-market sale 10K sh $11.28K @ $1.13
  • 2025-11-19 Hamilton Alex P. Director
    Open-market sale 125K sh $152.88K @ $1.22
  • 2026-03-16 Cohen Jacob D. Chief Executive Officer Officer · Director · 10% Owner
    Grant/Award 2.13M sh 3 fills derivative
  • 2025-09-09 JOHNSTON EUGENE M Chief Financial Officer Officer
    Grant/Award 100K sh
  • 2025-09-09 Cohen Jacob D. Chief Executive Officer Officer · Director · 10% Owner
    Grant/Award 500K sh
  • 2025-09-09 Cohen Jacob D. Chief Executive Officer Officer · Director · 10% Owner
    Grant/Award 2M sh derivative
  • 2025-09-09 MYERS KENNY Director
    Grant/Award 100K sh
  • 2025-09-09 D'Alessio Lorraine Pamela Director
    Grant/Award 100K sh
  • 2025-09-09 Hamilton Alex P. Director
    Grant/Award 100K sh
  • 2025-07-21 Cohen Jacob D. Chief Executive Officer Officer · Director · 10% Owner
    Grant/Award 50K sh 2 fills derivative
  • 2026-03-16 Cohen Jacob D. Chief Executive Officer Officer · Director · 10% Owner
    Non-cash transfer 2.13M sh 3 fills derivative
  • 2025-06-05 Cohen Jacob D. Chief Executive Officer Officer · Director · 10% Owner
    Gift 400K sh 2 fills
From SEC Form 4 + 5 (insider beneficial-ownership filings) · last 12 months · view all on SEC EDGAR ↑
$0.42
52-week range $0.16 – $2.75
Market cap
$7.25M
Volume
111.9K (0.1× avg)
3-mo avg 754.4K
Price snapshot as of 2026-05-21 16:11 UTC (Market snapshot (OPEN))

show_chartPrice Chart

Loading chart...

feed MGRX - Latest Insights

MGRX
May 19, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
9
Mangoceuticals Reports Severe Cash Drain, Reiterates Going Concern, Faces Nasdaq Delisting, and Discloses Controversial CEO Subsidiary Agreement
Sentiment: Negative
View Wiseek Article
MGRX
Apr 01, 2026, 6:31 AM EDT
Filing Type: 10-K
Importance Score:
10
MANGOCEUTICALS Faces Delisting Amid Soaring Losses, CEO Option Repricing, and Related Party Control of Core Assets
Sentiment: Negative
View Wiseek Article
MGRX
Mar 17, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
9
Mangoceuticals Reprices CEO Options, Files $73M Lawsuit Against Former Consultant
Sentiment: Neutral
View Wiseek Article
MGRX
Mar 17, 2026, 4:00 PM EDT
Source: GlobeNewswire
Importance Score:
9
Mangoceuticals Sues Former Tech Firm for $73M+ Over Failed Platform Delivery
Sentiment: Neutral
View Wiseek Article
MGRX
Mar 06, 2026, 4:02 PM EST
Source: Reuters
Importance Score:
7
Mangoceuticals Seeks Patent Expansion for MGX-0024 Antiviral to Cover Animal and Bird Infections
Sentiment: Positive
View Wiseek Article
MGRX
Feb 23, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
Mangoceuticals' MGX-0024 Shows Strong Antiviral Efficacy in Poultry Trials, H5N1 Study
Sentiment: Positive
View Wiseek Article
MGRX
Feb 19, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
Mangoceuticals Reports 336% MoM Sales Growth for Injectable TRT Program, Cuts Customer Acquisition Costs by 54%
Sentiment: Positive
View Wiseek Article
MGRX
Feb 06, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
9
Mangoceuticals Receives Nasdaq Delisting Notice for Sub-$1.00 Bid Price
Sentiment: Negative
View Wiseek Article
MGRX
Jan 23, 2026, 5:07 PM EST
Filing Type: S-1/A
Importance Score:
9
Amended S-1 Details Resale of 2.64M Shares by Selling Stockholders, Reinforcing Dilution Concerns Amidst Going Concern Warning
Sentiment: Negative
View Wiseek Article
MGRX
Jan 13, 2026, 5:30 PM EST
Filing Type: S-1
Importance Score:
9
Resale Registration of 2.64M Shares by Selling Stockholders Amidst Going Concern Warning and Eli Lilly Lawsuit
Sentiment: Negative
View Wiseek Article